<p>HBW Advisory Services LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第二季度增持了 27.9% 的礼来公司（NYSE:LLY - 免费报告）股份。这家机构投资者在此期间购买了额外的 459 股后，持有该公司 2,107 股股票。截至其最近向证券交易委员会（SEC）提交的文件，HBW Advisory Services LLC 在礼来公司的持股价值为 1,643,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>先锋集团的 VUG ETF：您投资组合的终极成长 ETF</li>
</ul>
<p>其他一些对冲基金也调整了对 LLY 的持股。Brighton Jones LLC 在第四季度增持了 22.0% 的礼来公司股份。Brighton Jones LLC 现在持有 9,597 股该公司股票，价值 7,409,000 美元，此前在此期间购买了额外的 1,730 股。Revolve Wealth Partners LLC 在第四季度增持了 2.8% 的礼来公司股份。Revolve Wealth Partners LLC 现在持有 1,471 股该公司股票，价值 1,136,000 美元，此前在此期间收购了额外的 40 股。Orion Capital Management LLC 在第四季度增持了 2.5% 的礼来公司股份。Orion Capital Management LLC 现在持有 1,610 股该公司股票，价值 1,243,000 美元，此前在此期间收购了额外的 40 股。Pictet 银行欧洲股份有限公司在第四季度增持了 4.1% 的礼来公司股份。Pictet 银行欧洲股份有限公司现在持有 64,758 股该公司股票，价值 49,993,000 美元，此前在此期间收购了额外的 2,568 股。最后，Breed's Hill Capital LLC 在第四季度增持了 212.0% 的礼来公司股份。Breed's Hill Capital LLC 现在持有 1,426 股该公司股票，价值 1,101,000 美元，此前在此期间收购了额外的 969 股。82.53% 的股票由机构投资者和对冲基金持有。</p>
<h2>礼来公司股票表现</h2>
<p>礼来公司股票周五开盘价为 754.90 美元。礼来公司的年低为 623.78 美元，年高为 942.35 美元。该公司的市值为 7144.8 亿美元，市盈率为 49.34，PEG 比率为 1.05，贝塔系数为 0.47。该公司的债务股本比为 1.86，速动比率为 1.00，流动比率为 1.28。该公司的 50 日移动平均价格为 741.03 美元，200 日移动平均价格为 776.40 美元。</p>
<ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近于 8 月 7 日（星期四）公布了季度财报。该公司报告季度每股收益为 6.31 美元，超出分析师一致预期的 5.59 美元，超出幅度为 0.72 美元。礼来公司的股本回报率为 92.72%，净利润率为 25.91%。该公司季度收入为 155.6 亿美元，而一致预期为 144 亿美元。去年同期，该公司的每股收益为 3.92 美元。与去年同期相比，该公司的收入增长了 37.6%。礼来公司已将 2025 财年的指导目标设定为 21.750-23.000 美元每股收益。研究分析师平均预测礼来公司本年度每股收益为 23.48 美元。</p>
<h2>礼来公司宣布分红</h2>
<p>该公司最近还披露了季度分红，分红于 9 月 10 日（星期三）支付。8 月 15 日（星期五）登记在册的投资者获得每股 1.50 美元的分红。除息日为 8 月 15 日（星期五）。这代表着年化分红为 6.00 美元，收益率为 0.8%。礼来公司的分红支付比率（DPR）目前为 39.22%。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>Ozempic 热潮：Hims 与礼来公司引领医疗保健投资</li>
</ul>
<p>几家研究公司最近对 LLY 发表了评论。Cantor Fitzgerald 将礼来公司的目标价从 975.00 美元下调至 825.00 美元，并在 8 月 13 日（星期三）的报告中对该股票给予了 “增持” 评级。Erste Group Bank 在 6 月 5 日（星期四）的研究报告中将礼来公司的评级从 “买入” 下调至 “持有”。汇丰全球研究在 8 月 27 日（星期三）的研究报告中将礼来公司的评级从 “适度卖出” 上调至 “持有”。Guggenheim 在 8 月 13 日（星期三）的研究报告中将礼来公司的目标价从 942.00 美元下调至 875.00 美元，并对该股票给予了 “买入” 评级。最后，大和资本市场在 8 月 17 日（星期日）的研究报告中将礼来公司的评级从 “跑赢大盘” 下调至 “中性”，并设定了 700.00 美元的目标价。一位股票研究分析师对该股票给予了强烈买入评级，十三位给予了买入评级，八位对该公司的股票给予了持有评级。根据 MarketBeat，礼来公司的共识评级为 “适度买入”，共识目标价为 941.35 美元。</p>
<p><strong>查看我们关于礼来公司的最新股票报告</strong></p>
<h2>内部活动</h2>
<p>在礼来公司的其他消息中，董事 Gabrielle Sulzberger 于 8 月 12 日星期二购买了 117 股该公司的股票。股票的平均购买价格为每股 641.18 美元，总价值为 75,018.06 美元。完成购买后，该董事直接持有公司 2,703 股股票，价值为 1,733,109.54 美元。此次交易使其持股增加了 4.52%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接查看。此外，首席执行官 David A. Ricks 于 8 月 12 日星期二购买了 1,632 股该公司的股票。股票的平均成本为每股 644.77 美元，总价值为 1,052,264.64 美元。购买后，首席执行官持有 546,601 股公司的股票，价值为 352,431,926.77 美元。此次交易使其持股增加了 0.30%。该购买的披露信息可以在这里找到。在过去 90 天内，内部人士共购买了 4,514 股公司股票，价值为 2,894,841 美元。内部人士持有 0.13% 的股票。</p>
<h2>礼来公司简介</h2>
<p>（免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素 lispro、胰岛素 lispro 原料、胰岛素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>乘坐奢侈零售浪潮，投资这三只高端品牌股票</li>
<li>股票行业对成功投资的重要性</li>
<li>华尔街悄然对这些中国科技巨头下注</li>
<li>加拿大债券市场假期：如何投资和交易</li>
<li>Meta 的 6000 亿美元美国投资：对股票是看跌还是看涨？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在考虑投资礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正悄悄地向客户推荐在市场广泛关注之前购买……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>HBW Advisory Services LLC 在第二季度将其在礼来公司的股份增加了 27.9%，目前持有 2,107 股，价值 164 万美元。其他对冲基金也增加了他们的持股。礼来的股票开盘价为 754.90 美元，市值为 7144.8 亿美元。该公司报告第二季度每股收益为 6.31 美元，超出预期，并将 2025 财年的指引设定为每股收益 21.750-23.000 美元。最近支付的季度股息为每股 1.50 美元，收益率为 0.8%</p>

<p>HBW Advisory Services LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 27.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,107 shares of the company's stock after buying an additional 459 shares during the period. HBW Advisory Services LLC's holdings in Eli Lilly and Company were worth $1,643,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>HBW Advisory Services LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第二季度增持了 27.9% 的礼来公司（NYSE:LLY - 免费报告）股份。这家机构投资者在此期间购买了额外的 459 股后，持有该公司 2,107 股股票。截至其最近向证券交易委员会（SEC）提交的文件，HBW Advisory Services LLC 在礼来公司的持股价值为 1,643,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio</li>
</ul>
<div class="lb-trans"><ul>
<li>先锋集团的 VUG ETF：您投资组合的终极成长 ETF</li>
</ul>
</div><p>A number of other hedge funds have also modified their holdings of LLY. Brighton Jones LLC increased its holdings in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC grew its holdings in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after acquiring an additional 40 shares during the period. Orion Capital Management LLC grew its holdings in Eli Lilly and Company by 2.5% during the fourth quarter. Orion Capital Management LLC now owns 1,610 shares of the company's stock worth $1,243,000 after acquiring an additional 40 shares during the period. Bank Pictet &amp; Cie Europe AG grew its holdings in Eli Lilly and Company by 4.1% during the fourth quarter. Bank Pictet &amp; Cie Europe AG now owns 64,758 shares of the company's stock worth $49,993,000 after acquiring an additional 2,568 shares during the period. Finally, Breed s Hill Capital LLC grew its holdings in Eli Lilly and Company by 212.0% during the fourth quarter. Breed s Hill Capital LLC now owns 1,426 shares of the company's stock worth $1,101,000 after acquiring an additional 969 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些对冲基金也调整了对 LLY 的持股。Brighton Jones LLC 在第四季度增持了 22.0% 的礼来公司股份。Brighton Jones LLC 现在持有 9,597 股该公司股票，价值 7,409,000 美元，此前在此期间购买了额外的 1,730 股。Revolve Wealth Partners LLC 在第四季度增持了 2.8% 的礼来公司股份。Revolve Wealth Partners LLC 现在持有 1,471 股该公司股票，价值 1,136,000 美元，此前在此期间收购了额外的 40 股。Orion Capital Management LLC 在第四季度增持了 2.5% 的礼来公司股份。Orion Capital Management LLC 现在持有 1,610 股该公司股票，价值 1,243,000 美元，此前在此期间收购了额外的 40 股。Pictet 银行欧洲股份有限公司在第四季度增持了 4.1% 的礼来公司股份。Pictet 银行欧洲股份有限公司现在持有 64,758 股该公司股票，价值 49,993,000 美元，此前在此期间收购了额外的 2,568 股。最后，Breed's Hill Capital LLC 在第四季度增持了 212.0% 的礼来公司股份。Breed's Hill Capital LLC 现在持有 1,426 股该公司股票，价值 1,101,000 美元，此前在此期间收购了额外的 969 股。82.53% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Eli Lilly and Company Stock Performance</h2>
<div class="lb-trans"><h2>礼来公司股票表现</h2>
</div><p>Shares of Eli Lilly and Company stock opened at $754.90 on Friday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $942.35. The company has a market cap of $714.48 billion, a price-to-earnings ratio of 49.34, a PEG ratio of 1.05 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The business's 50 day moving average price is $741.03 and its 200 day moving average price is $776.40.</p>
<div class="lb-trans"><p>礼来公司股票周五开盘价为 754.90 美元。礼来公司的年低为 623.78 美元，年高为 942.35 美元。该公司的市值为 7144.8 亿美元，市盈率为 49.34，PEG 比率为 1.05，贝塔系数为 0.47。该公司的债务股本比为 1.86，速动比率为 1.00，流动比率为 1.28。该公司的 50 日移动平均价格为 741.03 美元，200 日移动平均价格为 776.40 美元。</p>
</div><ul>
<li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li>
</ul>
<div class="lb-trans"><ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the business posted $3.92 earnings per share. The firm's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近于 8 月 7 日（星期四）公布了季度财报。该公司报告季度每股收益为 6.31 美元，超出分析师一致预期的 5.59 美元，超出幅度为 0.72 美元。礼来公司的股本回报率为 92.72%，净利润率为 25.91%。该公司季度收入为 155.6 亿美元，而一致预期为 144 亿美元。去年同期，该公司的每股收益为 3.92 美元。与去年同期相比，该公司的收入增长了 37.6%。礼来公司已将 2025 财年的指导目标设定为 21.750-23.000 美元每股收益。研究分析师平均预测礼来公司本年度每股收益为 23.48 美元。</p>
</div><h2>Eli Lilly and Company Announces Dividend</h2>
<div class="lb-trans"><h2>礼来公司宣布分红</h2>
</div><p>The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were given a dividend of $1.50 per share. The ex-dividend date was Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 39.22%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，分红于 9 月 10 日（星期三）支付。8 月 15 日（星期五）登记在册的投资者获得每股 1.50 美元的分红。除息日为 8 月 15 日（星期五）。这代表着年化分红为 6.00 美元，收益率为 0.8%。礼来公司的分红支付比率（DPR）目前为 39.22%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Ozempic Boom: Hims &amp; Eli Lilly Lead Healthcare Bets</li>
</ul>
<div class="lb-trans"><ul>
<li>Ozempic 热潮：Hims 与礼来公司引领医疗保健投资</li>
</ul>
</div><p>Several research firms recently commented on LLY. Cantor Fitzgerald dropped their target price on Eli Lilly and Company from $975.00 to $825.00 and set an &#34;overweight&#34; rating on the stock in a report on Wednesday, August 13th. Erste Group Bank downgraded Eli Lilly and Company from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, June 5th. Hsbc Global Res upgraded Eli Lilly and Company from a &#34;moderate sell&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, August 27th. Guggenheim lowered their price target on Eli Lilly and Company from $942.00 to $875.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, August 13th. Finally, Daiwa Capital Markets downgraded Eli Lilly and Company from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat, Eli Lilly and Company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $941.35.</p>
<div class="lb-trans"><p>几家研究公司最近对 LLY 发表了评论。Cantor Fitzgerald 将礼来公司的目标价从 975.00 美元下调至 825.00 美元，并在 8 月 13 日（星期三）的报告中对该股票给予了 “增持” 评级。Erste Group Bank 在 6 月 5 日（星期四）的研究报告中将礼来公司的评级从 “买入” 下调至 “持有”。汇丰全球研究在 8 月 27 日（星期三）的研究报告中将礼来公司的评级从 “适度卖出” 上调至 “持有”。Guggenheim 在 8 月 13 日（星期三）的研究报告中将礼来公司的目标价从 942.00 美元下调至 875.00 美元，并对该股票给予了 “买入” 评级。最后，大和资本市场在 8 月 17 日（星期日）的研究报告中将礼来公司的评级从 “跑赢大盘” 下调至 “中性”，并设定了 700.00 美元的目标价。一位股票研究分析师对该股票给予了强烈买入评级，十三位给予了买入评级，八位对该公司的股票给予了持有评级。根据 MarketBeat，礼来公司的共识评级为 “适度买入”，共识目标价为 941.35 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>查看我们关于礼来公司的最新股票报告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, CEO David A. Ricks bought 1,632 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.13% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在礼来公司的其他消息中，董事 Gabrielle Sulzberger 于 8 月 12 日星期二购买了 117 股该公司的股票。股票的平均购买价格为每股 641.18 美元，总价值为 75,018.06 美元。完成购买后，该董事直接持有公司 2,703 股股票，价值为 1,733,109.54 美元。此次交易使其持股增加了 4.52%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接查看。此外，首席执行官 David A. Ricks 于 8 月 12 日星期二购买了 1,632 股该公司的股票。股票的平均成本为每股 644.77 美元，总价值为 1,052,264.64 美元。购买后，首席执行官持有 546,601 股公司的股票，价值为 352,431,926.77 美元。此次交易使其持股增加了 0.30%。该购买的披露信息可以在这里找到。在过去 90 天内，内部人士共购买了 4,514 股公司股票，价值为 2,894,841 美元。内部人士持有 0.13% 的股票。</p>
</div><h2>Eli Lilly and Company Profile</h2>
<div class="lb-trans"><h2>礼来公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素 lispro、胰岛素 lispro 原料、胰岛素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Ride the Luxury Retail Wave with These 3 High-End Brand Stocks</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Wall Street Quietly Bets Big on These Chinese Tech Giants</li>
<li>Canada Bond Market Holiday: How to Invest and Trade</li>
<li>Meta's $600B U.S. Investment: Bearish or Bullish for Shares?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>乘坐奢侈零售浪潮，投资这三只高端品牌股票</li>
<li>股票行业对成功投资的重要性</li>
<li>华尔街悄然对这些中国科技巨头下注</li>
<li>加拿大债券市场假期：如何投资和交易</li>
<li>Meta 的 6000 亿美元美国投资：对股票是看跌还是看涨？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正悄悄地向客户推荐在市场广泛关注之前购买……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HBW Advisory Services LLC 购买了礼来公司 $LLY 的股票